Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022

Rhea-AI Summary

Vincerx Pharma, Inc. (Nasdaq: VINC) announced three poster presentations for the 64th American Society of Hematology (ASH) Annual Meeting, set for December 10-13, 2022, in New Orleans and virtually. Key presentations include:

• VIP943: A novel CD123 antibody drug conjugate for acute myeloid leukemia (AML).
• Enitociclib: A CDK9 inhibitor showing safety and early efficacy signs in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
• Preclinical Study: Enitociclib's combination studies in multiple myeloma.

Details and materials will be available on the company's website after the presentations.

Positive

• Participation in a major industry event showcasing promising drug candidates.
• Three presentations highlighting the company's innovative approaches in cancer therapeutics.
• Potential for increased visibility and investor interest through ASH participation.

Negative

• None.

PALO ALTO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced three poster presentations at the upcoming 64^th American Society of Hematology (ASH) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from December 10-13, 2022.

Poster presentation details:

Poster Title:	VIP943 Is a Novel CD123 Antibody Drug Conjugate with in Vitro and In Vivo Efficacy in Acute Myeloid Leukemia (AML) Models
Publication Number:	2650
Presenter:	Beatrix Stelte-Ludwig, PhD
Session Type:	In-Person and e-Poster Presentation
Session Name:	604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Session Date and Time:	Sunday, December 11, 2022 at 6:00PM CT
Location:	Ernest N. Morial Convention Center, Hall D

Poster presentation details:

Poster Title:	Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor: Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Publication Number:	4256
Presenter:	Mazyar Shadman, MD
	Fred Hutchinson Cancer Research Center
Session Type:	In-Person and e-Poster Presentation
Session Name:	626. Aggressive Lymphomas: Prospective Therapeutic Trials: Poster III
Session Date and Time:	Sunday, December 11, 2022 at 6:00 PM CT
Location:	Ernest N. Morial Convention Center, Hall D

Poster presentation details:

Poster Title:	Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma
Publication Number:	4793
Presenter:	Andy Son Tran, BSc
Session Type:	In-Person and e-Poster Presentation
Session Name:	802. Chemical Biology and Experimental Therapeutics: Poster III
Session Date and Time:	Monday, December 12, 2022at 6:00 PM CT
Location:	Ernest N. Morial Convention Center, Hall D

A copy of the presentation materials can be accessed on the Investors section of the Company’s website at www.vincerx.com once the presentation has concluded.

About Vincerx Pharma, Inc.
Vincerx Pharma, Inc. (Vincerx) is a clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage modular bioconjugation platform, which includes next-generation antibody-drug conjugates and innovative small molecule drug conjugates. For more information, please visit www.vincerx.com.

Contacts
Bruce Mackle
LifeSci Advisors, LLC
646-889-1200
bmackle@lifesciadvisors.com

FAQ

What will Vincerx present at the ASH Annual Meeting 2022?

Vincerx will present three posters focusing on VIP943, Enitociclib, and preclinical studies in cancer therapies.

When is the 64th ASH Annual Meeting?

The ASH Annual Meeting will take place from December 10-13, 2022.

Where is the ASH Annual Meeting held?

The ASH Annual Meeting is being held in New Orleans, Louisiana, as well as virtually.

What is Enitociclib being studied for?

Enitociclib is being studied for its efficacy and safety in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

How can I access Vincerx's presentation materials?

Presentation materials will be accessible in the Investors section of Vincerx's website after the presentations.